Effects of hypolipemic drugs on psoriasis

Psoriasis is a chronic, systematic, inflammatory disease in which, multiple metabolic and immunologic disturbances lead to lipid abnormalities, impaired glucose tolerance, metabolic syndrome, diabetes mellitus, atherosclerosis, hypertension, ischemic heart disease, and numerous metabolic disorders. In clinical practice, the most commonly used drugs in treatment of lipid abnormalities are statins and fibrates. Statins are characterized by pleiotropic effects, such as antioxidant, anti-inflammatory, anticoagulant, antiproliferative. They work by reducing concentration of low-density lipoprotein (LDL), total cholesterol, triglycerides, and stabilize atherosclerotic plaque. Fibrates are medications, which help to lower triglycerides, LDL, very low-density lipoprotein (VLDL) levels and increase lower high-density lipoprotein (HDL). In recent years, many new drugs were found to normalize lipid profile in patients with psoriasis: glitazones (pioglitazone, troglitazone), and glucagon-like peptide-1 (GLP-1) receptor agonists. Pioglitazone improves lipid profile including decrease of triglicerydes, fatty acids, LDL, and increase of HDL.Glucagon-like peptide 1 (GLP-1) analogues decrease modestlylow-density lipoprotein cholesterol (LDL-C), total cholesterol and triglycerides. The purpose of this study is to assess the current state of knowledge on the effect of different hypolipemic treatments on the course of psoriasis. The study includes literature from medical databases: Pubmed and Google Scholar. We were browsing the PubMed and Google Scholar untill the beginning of December. The systematic review includes 41 eligible original articles.

PRISMA checklist.docx